摘要
目的 :观察金双歧治疗乙肝肝硬化的疗效 ,其改善症状、体征及肝功能的效应。方法 :86例住院的乙肝肝硬化患者随机分为试验组 (43例 )与对照组 (43例 ) ,试验组在普通支持疗法的基础上加用金双歧片 12片 /日 ,对照组仅用普通支持疗法 ,疗程均为 2个月。疗程结束后 ,比较两组症状、体征及肝功能改善情况。结果 :治疗后 ,试验组、腹胀、腹泻及便秘症状的缓解率均明显高于对照组 (P<0 .0 1) ,纳差、乏力症状的缓解率高于对照组 (P>0 .0 5 ) ;试验组的 AL T复常率、TBil复常率明显高于对照组 (P<0 .0 1) ,血氨及Child- Pugh分数试验组明显低于对照组 (P<0 .0 1) ;AST复常率、AL B复常率高于对照组 ,但无统计学意义 (P<0 .0 5 )。结论 :金双歧治疗乙肝肝硬化安全有效 。
Objective:To observe the efficacy of Bifid Triple Viable Tablet in the treatment of HBV related cirrhosis Methods:86 hospitalized patients with HBV related cirrhosis were randomized into trial group ( n =43) and control group ( n =43) The patients in the trial group were given general supportive therapy plus Bifid Triple Viable,while those in control group were given general supportive only After two months therapy,parmeters observed were compared Results:After therapy,the remission rate of abdominal distension,diarrhea and constipation (80 0%,87 5%,88 9% respectively) of trial group were higher than those of control group (P<0 01);Mean serum ammonia[(48 0±27 4)μmol/L]and Child Pugh score(4 3±1 4)of trail group are significantly lower than that of control group ( P <0 01) The normalization rate of ALT,T Bil and (77 2%,53 5% respectively) of trail group is higher than those of control group( P <0 01);The normalization rate of AST,ALB(21 5%,80 1% respectively) of trail group is higher than those of control group,but there exists no statistic difference( P <0 05) Conclusion:Bifid Triple Viable Tablet not only effectively relieves the symptoms and signs in HBV related cirhosis but also improves biochemical profile Bifid Triple Viable Tablet is well tolerated,no adverse effects were found during the treating period
出处
《中国微生态学杂志》
CAS
CSCD
2002年第3期160-161,共2页
Chinese Journal of Microecology
